167 related articles for article (PubMed ID: 31165087)
1. Risk of Corneal Graft Rejection After High-risk Keratoplasty Following Fine-needle Vessel Coagulation of Corneal Neovascularization Combined With Bevacizumab: A Pilot Study.
Hos D; Le VNH; Hellmich M; Siebelmann S; Roters S; Bachmann BO; Cursiefen C
Transplant Direct; 2019 May; 5(5):e452. PubMed ID: 31165087
[TBL] [Abstract][Full Text] [Related]
2. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation.
Dohlman TH; Singh RB; Amparo F; Carreno-Galeano T; Dastjerdi M; Coco G; Di Zazzo A; Shikari H; Saboo U; Sippel K; Ciralsky J; Yoo SH; Sticca M; Wakamatsu TH; Murthy S; Hamrah P; Jurkunas U; Ciolino JB; Saeed H; Gomes JAP; Perez VL; Yin J; Dana R
Ophthalmol Sci; 2024; 4(4):100492. PubMed ID: 38682029
[TBL] [Abstract][Full Text] [Related]
4. [Preconditioning of vascularized high-risk eyes using fine-needle diathermy and cross-linking].
Matthaei M; Hos D; Bock F; Le VNH; Hou Y; Schaub F; Siebelmann S; Zhang W; Roters S; Bachmann BO; Cursiefen C
Ophthalmologe; 2021 Jun; 118(6):553-560. PubMed ID: 33961088
[TBL] [Abstract][Full Text] [Related]
5. Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival.
Fasciani R; Mosca L; Giannico MI; Ambrogio SA; Balestrazzi E
Int Ophthalmol; 2015 Apr; 35(2):221-7. PubMed ID: 24715230
[TBL] [Abstract][Full Text] [Related]
6. Cutting Edge: Novel Treatment Options Targeting Corneal Neovascularization to Improve High-Risk Corneal Graft Survival.
Cursiefen C; Hos D
Cornea; 2021 Dec; 40(12):1512-1518. PubMed ID: 34116541
[TBL] [Abstract][Full Text] [Related]
7. [Standardized semiquantitative analysis of corneal neovascularization using projected corneal photographs--pilot study after perforating corneal keratoplasty before immune reaction].
Cursiefen C; Wenkel H; Martus P; Langenbucher A; Seitz B; Küchle M
Klin Monbl Augenheilkd; 2001 Jul; 218(7):484-91. PubMed ID: 11512248
[TBL] [Abstract][Full Text] [Related]
8. Avastin use in high risk corneal transplantation.
Vassileva PI; Hergeldzhieva TG
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1701-6. PubMed ID: 19680676
[TBL] [Abstract][Full Text] [Related]
9. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
10. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
[TBL] [Abstract][Full Text] [Related]
11. [Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy].
Hamdan J; Boulze M; Aziz A; Alessi G; Hoffart L
J Fr Ophtalmol; 2015 Dec; 38(10):924-33. PubMed ID: 26522892
[TBL] [Abstract][Full Text] [Related]
12. Combined scraping, coagulation, and subconjunctival bevacizumab in Descemet stripping automated endothelial keratoplasty for bullous keratopathy.
Chiang CC; Lin JM; Tsai YY
Eur J Ophthalmol; 2013; 23(3):309-15. PubMed ID: 23161181
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.
Gerten G
Cornea; 2008 Dec; 27(10):1195-9. PubMed ID: 19034142
[TBL] [Abstract][Full Text] [Related]
14. [Management of corneal neovascularization prior to corneal transplantation: Report of 112 cases].
Belghmaidi S; Hajji I; Ennassiri W; Benhaddou R; Baha Ali T; Moutaouakil A
J Fr Ophtalmol; 2016 Jun; 39(6):515-20. PubMed ID: 27324233
[TBL] [Abstract][Full Text] [Related]
15. Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.
Dekaris I; Gabrić N; Drača N; Pauk-Gulić M; Miličić N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):287-94. PubMed ID: 25398659
[TBL] [Abstract][Full Text] [Related]
16. Corneal graft surgery combined with subconjunctival bevacizumab (avastin).
Symes RJ; Poole TR
Cornea; 2010 Jun; 29(6):691-3. PubMed ID: 20458243
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of trichostatin on allograft rejection of corneal transplantation in rats.
Maimaitiming R; Yang X; Wupuer K; Ye N; Pan Z
Int J Clin Exp Med; 2015; 8(8):12424-9. PubMed ID: 26550154
[TBL] [Abstract][Full Text] [Related]
18. UV light-mediated corneal crosslinking as (lymph)angioregressive pretreatment to promote graft survival after subsequent high-risk corneal transplantation (CrossCornealVision): protocol for a multicenter, randomized controlled trial.
Wiedemann J; Hos D; Limburg E; Zettelmeyer U; Schiller P; Franklin J; Bachmann B; Böhringer D; Dietrich-Ntoukas T; Fuchsluger TA; Geerling G; Lang SJ; Mayer WJ; Priglinger S; Reinhard T; Seitz B; Cursiefen C
Trials; 2024 Mar; 25(1):169. PubMed ID: 38448965
[TBL] [Abstract][Full Text] [Related]
19. Comparison of photodynamic therapy with two different parameters combined with subconjunctival injection of bevacizumab for corneal neovascularization.
Yin XF; Wu MH; Jin CJ; Zhou SY
Photodiagnosis Photodyn Ther; 2024 Apr; 46():104067. PubMed ID: 38548042
[TBL] [Abstract][Full Text] [Related]
20. Long-term topical bevacizumab for prevention of corneal graft rejections.
Kuo HH; Shen EP
Eur J Ophthalmol; 2021 Nov; 31(6):NP48-NP52. PubMed ID: 32613854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
